Lubrizol and Polyhose ink MoU to set up medical tube manufacturing facility in Tamil Nadu
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Growth markets revenue increased by 44 YoY to Rs. 812 crore
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants
Subscribe To Our Newsletter & Stay Updated